Limits...
Acceleration of periosteal bone formation by human basic fibroblast growth factor containing a collagen-binding domain from Clostridium histolyticum collagenase.

Uchida K, Matsushita O, Naruse K, Mima T, Nishi N, Hattori S, Ogura T, Inoue G, Tanaka K, Takaso M - J Biomed Mater Res A (2013)

Bottom Line: However, repeated dosing is required for sustained therapeutic effect as the efficacy of bFGF decreases rapidly following its diffusion from bone defect sites.The affinity of the fusion protein towards collagen and demineralized bone matrix (DBM) was also confirmed by collagen-binding assays.Taken together, these properties suggest that the CB-bFGF/collagen composite is a promising material for bone repair in the clinical setting.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedic Surgery, Kitasato University School of Medicine, 1-15-1 Minami-ku Kitasato, Kanagawa, Japan.

Show MeSH

Related in: MedlinePlus

3D micro-CT analysis of rat femurs two weeks after grafting DBM loaded with CB-bFGF. A: 3D micro-CT image, A-1: PBS, A-2: 0.58 nmol bFGF, A-3: 0.58 nmol CB-bFGF. Green color: new bone; brown color: existing bone. The scale bars indicate 1 mm. B: New bone area, and C: Bone mineral content after grafting DBM with various amounts of either bFGF or CB-bFGF. Data are presented as the mean ± S.E. (n = 8). a: p < 0.05 compared with the control group. b: p < 0.05 compared with the dose-matched group. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4232007&req=5

fig04: 3D micro-CT analysis of rat femurs two weeks after grafting DBM loaded with CB-bFGF. A: 3D micro-CT image, A-1: PBS, A-2: 0.58 nmol bFGF, A-3: 0.58 nmol CB-bFGF. Green color: new bone; brown color: existing bone. The scale bars indicate 1 mm. B: New bone area, and C: Bone mineral content after grafting DBM with various amounts of either bFGF or CB-bFGF. Data are presented as the mean ± S.E. (n = 8). a: p < 0.05 compared with the control group. b: p < 0.05 compared with the dose-matched group. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

Mentions: Two weeks after being grafted onto rat femurs, bFGF/DBM and CB-bFGF/DBM (0.058 nmol bFGF protein) had significantly stimulated periosteal bone formation compared to PBS/DBM [Fig. 4(B)]. In the CB-bFGF/DBM-treated group, bone formation increased in a dose-dependent manner, whereas a plateau in bone formation was reached for bFGF/DBM at 0.058 nmol. New bone volume and bone mineral content in femurs treated with CB-bFGF/DBM (0.29 and 0.58 nmol CB-bFGF) were significantly higher than those of femurs treated with similarly prepared bFGF/DBM [Fig. 4(A–C)].


Acceleration of periosteal bone formation by human basic fibroblast growth factor containing a collagen-binding domain from Clostridium histolyticum collagenase.

Uchida K, Matsushita O, Naruse K, Mima T, Nishi N, Hattori S, Ogura T, Inoue G, Tanaka K, Takaso M - J Biomed Mater Res A (2013)

3D micro-CT analysis of rat femurs two weeks after grafting DBM loaded with CB-bFGF. A: 3D micro-CT image, A-1: PBS, A-2: 0.58 nmol bFGF, A-3: 0.58 nmol CB-bFGF. Green color: new bone; brown color: existing bone. The scale bars indicate 1 mm. B: New bone area, and C: Bone mineral content after grafting DBM with various amounts of either bFGF or CB-bFGF. Data are presented as the mean ± S.E. (n = 8). a: p < 0.05 compared with the control group. b: p < 0.05 compared with the dose-matched group. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4232007&req=5

fig04: 3D micro-CT analysis of rat femurs two weeks after grafting DBM loaded with CB-bFGF. A: 3D micro-CT image, A-1: PBS, A-2: 0.58 nmol bFGF, A-3: 0.58 nmol CB-bFGF. Green color: new bone; brown color: existing bone. The scale bars indicate 1 mm. B: New bone area, and C: Bone mineral content after grafting DBM with various amounts of either bFGF or CB-bFGF. Data are presented as the mean ± S.E. (n = 8). a: p < 0.05 compared with the control group. b: p < 0.05 compared with the dose-matched group. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Mentions: Two weeks after being grafted onto rat femurs, bFGF/DBM and CB-bFGF/DBM (0.058 nmol bFGF protein) had significantly stimulated periosteal bone formation compared to PBS/DBM [Fig. 4(B)]. In the CB-bFGF/DBM-treated group, bone formation increased in a dose-dependent manner, whereas a plateau in bone formation was reached for bFGF/DBM at 0.058 nmol. New bone volume and bone mineral content in femurs treated with CB-bFGF/DBM (0.29 and 0.58 nmol CB-bFGF) were significantly higher than those of femurs treated with similarly prepared bFGF/DBM [Fig. 4(A–C)].

Bottom Line: However, repeated dosing is required for sustained therapeutic effect as the efficacy of bFGF decreases rapidly following its diffusion from bone defect sites.The affinity of the fusion protein towards collagen and demineralized bone matrix (DBM) was also confirmed by collagen-binding assays.Taken together, these properties suggest that the CB-bFGF/collagen composite is a promising material for bone repair in the clinical setting.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedic Surgery, Kitasato University School of Medicine, 1-15-1 Minami-ku Kitasato, Kanagawa, Japan.

Show MeSH
Related in: MedlinePlus